At a glance
- Originator CV Therapeutics
- Developer CV Therapeutics; Nonindustrial source
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 14 Apr 2000 New profile
- 14 Apr 2000 Preclinical development for Coronary artery restenosis in USA (Unknown route)
- 14 Apr 2000 Preclinical development for Vascular restenosis in USA (Unknown route)